Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)

被引：11
|
作者：
Schwartzberg, Lee S.
Franco, Sandra X.
Florance, Allison
O'Rourke, Lisa
Maltzman, Julie
Johnston, Stephen
机构：
来源：
ONCOLOGIST | 2010年 / 15卷 / 03期
关键词：
D O I：
10.1634/theoncologist.2009-0240erratum
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [1] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
    Schwarzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (02): : 122 - 129
  • [2] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
    Johnston, Stephen
    Pippen, John, Jr.
    Pivot, Xavier
    Lichinitser, Mikhail
    Sadeghi, Saeed
    Dieras, Veronique
    Gomez, Henry Leonidas
    Romieu, Gilles
    Manikhas, Alexey
    Kennedy, M. John
    Press, Michael F.
    Maltzman, Julie
    Florance, Allison
    O'Rourke, Lisa
    Oliva, Cristina
    Stein, Steven
    Pegram, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5538 - 5546
  • [3] Quality of Life in Hormone Receptor-Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
    Sherrill, Beth
    Amonkar, Mayur M.
    Sherif, Bintu
    Maltzman, Julie
    O'Rourke, Lisa
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (09): : 944 - 953
  • [4] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
    Delea, T. E.
    Amdahl, J.
    Chit, A.
    Amonkar, M. M.
    CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
  • [5] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
    Sun, Maoben
    Cai, Liangzhen
    Chen, Min
    MEDICINE, 2023, 102 (24) : E33975
  • [6] Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+metastatic breast cancer (MBC): A quality-of-life (QOL) analysis
    Sherif, B. N.
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Sherrill, B.
    Amonkar, M.
    Sherif, B.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
  • [8] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Borrego, M. Ruiz
    De la Haba, J.
    Morales, S.
    Ramos, M.
    Velasco, A.
    Mendez, M.
    Carabantes, F.
    Barnadas, A.
    Garcia, M.
    Moreno, J. A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
  • [9] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Ruiz, Manuel
    De la Haba, Juan
    Morales, Serafin
    Ramos, Manuel
    Velasco, Amlia
    Mendez, Miguel
    Carabantes, Francisco
    Barnadas, Agusti
    Garcia, Maria
    Moreno, Jose A.
    ANNALS OF ONCOLOGY, 2004, 15 : 35 - 35
  • [10] Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study
    Ro, J.
    Pippen, J.
    Pivot, X.
    Manikhas, A.
    Fehrenbacher, L.
    Makris, A.
    Florance, A.
    Maltzman, J.
    O'Rourke, L.
    Johnson, S.
    CANCER RESEARCH, 2009, 69 (24) : 796S - 797S
12345